Product Pathways - Translational Control
SignalSilence® hnRNP LL siRNA II #8624
|Transfection||H (M) (Mk)|
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® hnRNP LL siRNA I #8651 (+), or SignalSilence® hnRNP LL siRNA II (+), using hnRNP LL Antibody #4783 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The hnRNP LL Antibody confirms silencing of hnRNP LL expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
SignalSilence® hnRNP LL siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit hnRNP LL expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM SignalSilence® hnRNP LL siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Heterogeneous nuclear ribonucleoprotein L-like (hnRNP LL) is a nuclear RNA-binding protein that shares 69% amino acid homology with hnRNP L, a component of the hnRNP complex that regulates mRNA formation, packaging, and processing (1). hnRNP LL is induced in activated T cells and functions as a critical regulator of alternative splicing of CD45, a tyrosine phosphatase crucial for T cell development and activation (2). hnRNP LL also regulates the splicing of CD44 and Stat5a (2). The four isoforms of hnRNP LL are generated by alternative splicing and are widely expressed in human tissues (3).
- Pinol-Roma, S. et al. (1989) J Cell Biol 109, 2575-87.
- Oberdoerffer, S. et al. (2008) Science 321, 686-91.
- Shur, I. et al. (2004) Gene 334, 113-21.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 8651 SignalSilence® hnRNP LL siRNA I
- 4783 hnRNP LL Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.